The Center for Alternatives to Animal Testing is an academic center affiliated with the Division of Toxicological Sciences in the Department of Environmental Health Sciences of the Johns Hopkins University Bloomberg School of Public Health.
Text Size:
TestSmart Pharmaceuticals
May 7-9, 2001
PIER 5 HOTEL
711 Eastern Avenue
Baltimore, Maryland
Sponsors: 3M, Bristol-Meyers Squibb Company, Huntingdon Life Sciences, Schering-Plough Research Institute, and Taconic Farms, Inc.
Proceedings for TestSmart--Pharmaceuticals: An Efficient and Humane Approach to Predictors of Potential Toxic Effects of Drugs
- TOXICITY RISK MANAGEMENT AND THE TOXICITY DATA CONTINUUM: A RATIONALE FOR DRUG SAFETY ASSESSMENT
James T. Mayne, Pfizer Global Research and Development - THE BIOTECHNOLOGY REVOLUTION AND THE EVOLUTION OF REGULATORY TOXICOLOGY: PREPARING FOR THE FUTURE
James T. MacGregor, National Center for Toxicological Research, Food and Drug Administration (FDA) - REQUIREMENTS FOR SAFETY EVALUATION OF PHARMACEUTICALS--WHAT DO WE NEED TO KNOW? HOW DO WE OBTAIN THE INFORMATION TODAY?
James T. MacGregor, National Center for Toxicological Research (NCTR), FDA - ICH APPROACHES TO REDUCING ANIMAL USE
Robert Osterberg, Center for Drug Evaluation and Research (CDER), FDA - ADME-TOX TESTING WITH IN VITRO HUMAN EXPERIMENTAL SYSTEMS
Albert Li, In Vitro Technologies, Inc - USE OF ALTERNATIVE MODELS FOR ASSESSMENT OF CARCINOGENIC POTENTIAL: RESULTS OF ILSI COLLABORATIVE STUDIES
Denise Robinson, International Life Sciences Institute (ILSI) - NONINVASIVE ANIMAL IMAGING: VALUE-ADDED TO ANIMAL STUDIES FOR SAFETY AND EFFICACY
David Lester, CDER, FDA - IN VIVO BIOPHOTONIC IMAGING; APPLICATIONS FOR INFECTIOUS DISEASE, ONCOLOGY AND GENE EXPRESSION
Anthony F. Purchio, Xenogen Corporation - COMPUTATIONAL TOXICOLOGY AND KNOWLEDGE BASES AT FDA/CDER
Joseph Contrera, CDER, FDA - TIERED APPROACHES TO TOXICITY TESTING: PHARMACEUTICAL INDUSTRY INITIATIVES IN IMPLEMENTING THE 3Rs
Oliver P. Flint, Bristol-Myers Squibb Co. - GENOMICS
Daniel Casciano, NCTR, FDA - BEYOND THE GENOME TO TISSUE PROTEOMICS
Emmanuel Petricoin, Center for Biological Evaluation and Research (CBER), FDA - A BIOINFORMATICS APPROACH TO IDENTIFY MICROARRAY GENE EXPRESSION TOXICANT SIGNATURE PATTERNS
Pierre Bushel, National Institute of Environmental Health Sciences (NIEHS), NIH - ALTWEB AND THE SEARCH FOR ALTERNATIVES
Lisa Libowitz, Johns Hopkins Center for Alternatives to Animal Testing - BREAKOUT SESSIONS
- Case Study--Building A Hypothetical Program Using Novel Technologies And Approaches To Drug Discovery And Development (Actual Examples To Be Used As Contributing Information.)
Co-Chairs: Roger G. Ulrich (Abbott Laboratories) - Ways To Implement 3Rs In The Pharmaceutical Industry
Co-Chairs: Andrew N. Rowan (Humane Society of the United States), Robert Osterberg (CDER, FDA), David Lester (CDER, FDA) - Genomics, Proteomics and Bioinformatics
Co-Chairs: Robin Wesselschmidt (Genome Systems Inc.), Emmanuel Petricoin (CBER, FDA), Daniel Casciano (NCTR, FDA) - Transgenic Animals--Current and Future Applications in Pharmaceutical Safety
Co-Chairs: Frank Sistare (CDER, FDA), Denise Robinson (ILSI) - Transgenic Animals and Mechanistic Toxicology
Leslie Recio, CIIT Centers for Health Research - Multi-drug Resistan Gene Knockout Model
Diane Umbenhauer, Merck - Application Of Human Cells In The Evaluation Of Drug Toxicity
Co-Chairs: Albert Li (In Vitro Technologies, Inc.), Jerry Collins (FDA), Joseph Tomaszewski, (NIH)
- Case Study--Building A Hypothetical Program Using Novel Technologies And Approaches To Drug Discovery And Development (Actual Examples To Be Used As Contributing Information.)